PriceTargets.com logo

Alector - ALEC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.70
  • Forecasted Upside: 152.77%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.42 As of 11/30/2023 01:00 AM ET
▼ -0.01 (-0.18%)

This chart shows the closing price for ALEC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alector Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALEC

Analyst Price Target is $13.70
▲ +152.77% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Alector in the last 3 months. The average price target is $13.70, with a high forecast of $41.00 and a low forecast of $4.00. The average price target represents a 152.77% upside from the last price of $5.42.

This chart shows the closing price for ALEC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Alector. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/5/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/3/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2023MizuhoLower TargetBuy ➝ Buy$10.00 ➝ $9.00Low
9/25/2023The Goldman Sachs GroupInitiated CoverageSell$4.00Low
9/22/2023Cantor FitzgeraldInitiated CoverageOverweight$13.00Low
8/11/2023MizuhoLower TargetBuy ➝ Buy$12.00 ➝ $10.00Low
8/8/2023Stifel NicolausLower TargetHold ➝ Hold$10.00 ➝ $8.00Low
8/7/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$10.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$41.00Low
5/5/2023BarclaysLower Target$14.00 ➝ $12.00Low
3/3/2023Morgan StanleyLower TargetEqual Weight$11.00 ➝ $10.00Low
3/3/2023MizuhoLower Target$15.00 ➝ $12.00Low
3/2/2023BTIG ResearchLower TargetBuy$54.00 ➝ $16.00Low
3/1/2023HC WainwrightReiterated RatingBuy$41.00Low
3/1/2023CitigroupLower TargetBuy$17.00 ➝ $12.00Low
1/24/2023Morgan StanleyLower TargetEqual Weight$13.00 ➝ $11.00Low
1/6/2023Bank of AmericaDowngradeBuy ➝ Neutral$24.00 ➝ $12.00Low
11/10/2022CitigroupLower TargetBuy$19.00 ➝ $17.00Low
9/9/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$27.00 ➝ $13.00Low
7/11/2022CitigroupLower TargetBuy$34.00 ➝ $19.00N/A
7/6/2022MizuhoInitiated CoverageBuy$15.00N/A
5/24/2022The Goldman Sachs GroupLower TargetSell$9.00 ➝ $6.00Low
5/11/2022BarclaysLower Target$42.00 ➝ $14.00High
4/12/2022The Goldman Sachs GroupInitiated CoverageSell$9.00Medium
3/16/2022HC WainwrightReiterated RatingBuy$41.00High
3/8/2022Stifel NicolausDowngradeBuy ➝ Hold$32.00 ➝ $18.00High
2/25/2022CitigroupLower TargetBuy$43.00 ➝ $40.00Medium
9/27/2021William BlairInitiated CoverageOutperform$33.00Low
8/3/2021The Goldman Sachs GroupBoost TargetBuy$29.00 ➝ $33.00Medium
7/16/2021Morgan StanleyBoost TargetOverweight$33.00 ➝ $57.00Low
7/7/2021HC WainwrightReiterated RatingBuy$41.00Low
7/6/2021CitigroupReiterated RatingBuy$31.00 ➝ $43.00High
7/2/2021The Goldman Sachs GroupReiterated RatingBuy$29.00N/A
4/19/2021Morgan StanleyBoost TargetOverweight$31.00 ➝ $33.00Low
1/15/2021Bank of AmericaInitiated CoverageBuy$35.00High
11/11/2020Smith Barney CitigroupLower Target$40.00 ➝ $31.00Low
7/29/2020BarclaysLower TargetOverweight$36.00 ➝ $32.00High
6/24/2020HC WainwrightInitiated CoverageBuy$41.00Low
6/4/2020Morgan StanleyBoost TargetOverweight$29.00 ➝ $31.00High
4/28/2020The Goldman Sachs GroupInitiated CoverageBuy$32.00Medium
4/15/2020Morgan StanleyBoost TargetOverweight$27.00 ➝ $29.00High
3/5/2020CitigroupInitiated CoverageBuyLow
2/27/2020BarclaysInitiated CoverageOverweightHigh
2/18/2020Stifel NicolausInitiated CoverageBuyHigh
12/16/2019CowenReiterated RatingBuyMedium
12/8/2019CowenReiterated RatingBuyHigh
11/27/2019BTIG ResearchInitiated CoverageBuy$28.00N/A
11/21/2019BTIG ResearchInitiated CoverageBuy$28.00Low
11/12/2019CowenReiterated RatingBuyLow
7/17/2019CowenReiterated RatingBuyHigh
5/13/2019CowenReiterated RatingBuyHigh
3/4/2019CowenInitiated CoverageOutperformHigh
3/4/2019SVB LeerinkInitiated CoverageOutperformHigh
3/4/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$27.00Low
3/4/2019BarclaysInitiated CoverageOverweight$27.00Low
3/4/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$26.00Low
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2023
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/31/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Alector logo
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $5.42
Low: $5.34
High: $5.64

50 Day Range

MA: $5.52
Low: $3.77
High: $6.98

52 Week Range

Now: $5.42
Low: $3.66
High: $9.86

Volume

869,202 shs

Average Volume

593,878 shs

Market Capitalization

$456.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Alector?

The following Wall Street research analysts have issued stock ratings on Alector in the last year: Bank of America Co., Barclays PLC, BTIG Research, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Mizuho, Morgan Stanley, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for ALEC.

What is the current price target for Alector?

10 Wall Street analysts have set twelve-month price targets for Alector in the last year. Their average twelve-month price target is $13.70, suggesting a possible upside of 152.8%. HC Wainwright has the highest price target set, predicting ALEC will reach $41.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $4.00 for Alector in the next year.
View the latest price targets for ALEC.

What is the current consensus analyst rating for Alector?

Alector currently has 1 sell rating, 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALEC, but not buy more shares or sell existing shares.
View the latest ratings for ALEC.

What other companies compete with Alector?

Other companies that are similar to Alector include Allogene Therapeutics, ProKidney, Adaptimmune Therapeutics, bluebird bio and Orchard Therapeutics. Learn More about companies similar to Alector.

How do I contact Alector's investor relations team?

Alector's physical mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (415) 231-5660 and its investor relations email address is [email protected]. The official website for Alector is www.alector.com. Learn More about contacing Alector investor relations.